ClinicalTrials.gg
RecruitingNCT06417736Updated May 16, 2024

Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women

An interventional study of Megestrol Acetate 40 MG in Endometrial Cancer Stage I and Endometrial Hyperplasia, sponsored by Women's Hospital School Of Medicine Zhejiang University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Women's Hospital School Of Medicine Zhejiang University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Dec 2023, registered May 2024).
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing Megestrol Acetate in Endometrial Neoplasms — 2 open to participants now, 3 under way, 1 of them phase 3. Megestrol Acetate · Endometrial Neoplasms.

Started
2023
the only one that year
No phase
Only one
of the 10
Registered
9th of 10
by date
Lead sponsor
1 of 10
Women's Hospital School Of Medicine Zhejiang University

Among the 10 studies testing Megestrol Acetate in Endometrial Neoplasms, this one is the only one that started in 2023, is the only one with no phase, and was the 9th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

2 of the 10 studies testing Megestrol Acetate in Endometrial Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About Megestrol Acetate

Megestrol Acetate: first FDA approval 1971 (MEGACE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Megestrol Acetate in Endometrial Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effect and adverse side effects of membrane-inhibiting formula plus oral progestins as fertility-preserving treatment in patients with early-stage endometrial cancer and endometrial hyperplasia research questions:When taken with oral progestins, does the drug membrane-inhibiting formula shorten the time required for complete endometrial remission? What medical problems do participants have when taking drug membrane-inhibiting formula plus oral progestins? Efficacy, side effects, recurrence, pregnancy, and time to obtain pregnancy in different molecular classifications of POLE-mutated, mismatch repair-deficient(MMRd), p53 wild type(p53wt), and p53-abnormal(p53abn).

Participants will: Take drug membrane-inhibiting formula plus oral progestins every day Visit the clinic once every 3 months for checkups, tests, and hysteroscopy Keep a diary of examination results and pathology

03

Conditions studied

  • Endometrial Cancer Stage I
  • Endometrial Hyperplasia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.18-45 years old with a strong desire to preserve fertility; 2. diagnosed with primary grade1 or grade2 endometrioid endometrial carcinoma and hyperplasia 3.no signs of suspicious myometrial invasion by enhanced magnetic resonance imaging (MRI) 4. no signs of suspicious extrauterine by enhanced computed tomography and CT scan of the Lungs

Exclusion criteria

Exclusion Criteria:

  • 1.have for pregnancy. 2.no fertility requiremen 3.have myometrial invasion or extrauterine 4. diagnosed with primary grade3 endometrioid endometrial carcinoma or non-endometrioid endometrial carcinoma 5.Any disease or symptom that may affect the implementation of the study or the interpretation of the results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    membrane-inhibiting formula combined with oral progestins

    Megestrol acetate(160mg/day) and membrane-inhibiting formula, 24weeks

    Drug: Megestrol Acetate 40 MG

Interventions

06

What researchers measure

Primary outcomes

  1. 24-week complete response(CR) rate

    The treatment response:complete response,no endometrial lesion

    Time frame: baseline,12 weeks after treatment,and 24 weeks of treatment

Secondary outcomes

  1. 36-week CR rate

    The treatment response:complete response,no endometrial lesion

    Time frame: baseline,12 weeks after treatment,24 weeks of treatment,36 weeks of treatment

  2. 48-week CR rate

    The treatment response:complete response,no endometrial lesion

    Time frame: baseline,12 weeks after treatment,24 weeks of treatment,36 weeks of treatment,48 weeks of treatment

  3. treatment-related adverse events

    analyze the safety of the drug

    Time frame: baseline,12 weeks after treatment,and 24 weeks of treatment

  4. recurrent rate

    cumulative recurrent rate

    Time frame: baseline,12 weeks after treatment,24 weeks of treatment,36 weeks of treatment,48 weeks of treatment

  5. pregnancy rate

    long term fertility results

    Time frame: 1-year after CR

Other outcomes

  1. CR in different molecular classification

    Efficacy in different molecular classification of POLE-mutated, mismatch repair-deficient(MMRd), p53 wild type(p53wt),and p53-abnormal(p53abn)

    Time frame: baseline,12 weeks after treatment,24 weeks of treatment,36 weeks of treatment,48 weeks of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jul 2025, 19 months after the start.

Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 19 months is below that.

Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2024
First posted
May 16, 2024
StartActual
Dec 1, 2023
Primary completionEst.
Jul 31, 2025
CompletionEst.
Dec 31, 2026
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06417736
Lead sponsor
Women's Hospital School Of Medicine Zhejiang University
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Dec 1, 2023
Primary completion
Jul 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 16, 2024

Study contacts

Yang Li, Doctor
Contact
5516015@zju.edu.cn
0086-18268165386
Yang Li, Doctor
principal investigator · Women's Hospital School Of Medicine Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion